Imugene Limited (ASX:IMU – Get Rating) insider Lesley Russell acquired 10,000,000 shares of Imugene stock in a transaction dated Tuesday, June 7th. The shares were bought at an average cost of A$0.05 ($0.03) per share, with a total value of A$450,000.00 ($323,741.01). The company has a debt-to-equity ratio of 0.03, a current ratio of 18.74 […]
The clinical-stage immune-oncology company announced it would collaborate with the NASDAQ-lister last week and has provided further information on the.
Combining Imugene’s oncolytic virus technology with Celularity’s allogeneic CAR T-cell therapy has the potential to become a novel approach to improve.